Company Profile
and short Details: ZYDUS CADILA
Zydus
Cadila is a fully integrated, global healthcare provider, with strengths all
along the pharmaceutical value chain. With a core competence in the field of
healthcare, Zydus Cadila provides total healthcare solutions ranging from
formulations, active pharmaceutical ingredients and animal healthcare products
to wellness products.
Recently,
the group launched Exemptia, the world’s first biosimilar for Adalimumab, the
largest selling therapy worldwide for inflammatory arthritis. Zydus is also the
only Indian pharma company to launch its own patented NCE – Lipaglyn, a novel
drug approved for the treatment of diabetic dyslipidemia.
From
a turnover of Rs. 250 crores in 1995, the group posted revenues of over Rs.
9600 crores in FY17. The group had posted a turnover of Rs. 4600 crores in FY
11, making it a billion dollar company. As a leading healthcare provider, it
aims to become a global research based pharmaceutical company by 2020.
No comments:
Post a Comment